Overview

Formed in 2008, Neovasc Inc. is a specialty medical device company that develops, manufactures, and markets products for the rapidly growing cardiovascular marketplace.

Its products include the Tiara™ technology in development for the transcatheter treatment of mitral valve disease, the Neovasc Reducer™ for the treatment of refractory angina.

To receive Neovasc news updates Register Now

JOIN US

EuroPCR Reducer Symposium

A Proven, Evidence-Based Therapy When Angina Persists?

Wednesday, 22 May, 2019   16:30 – 18:00
Palais des Congrés,  Room 243
Paris, France

Disclaimer: Neovasc Reducer is not approved in the U.S.

News

MORE

Presentations & Events

MORE

Stock Chart

MORE

Financial Reports

MORE

Board Governance

MORE

2019 Q1 Earnings Call

May 9, 2019 4:30 EST

MORE

Auditor

Grant Thornton LLP
Vancouver, BC

Legal Counsel

Blakes LLP
Vancouver, BC

Transfer Agent

Computershare
Vancouver, BC

Investor Relations

Chris Clark
Chief Financial Officer
investors@neovasc.com